Screen 100-1000x more VHH antibody sequences with the largest libraries on the market
Combining the largest and most diverse synthetic VHH libraries available with our proprietary, cell-free CIS display technology means that these uniquely vast libraries can reach their full potential in under half the time of traditional immunisation methods.
Appetite for destruction: ‘Plug and play’ targeted protein degradation using synthetic VHH antibodies to take out tricky targets
Novel VHH protein degraders developed using Isogenica’s VHH antibody libraries show anti-tumour activity in vivo.
Passionate about patient outcomes
With a shared passion for discovery and a collaborative spirit, our team works to advance the field and support the development of ground-breaking therapies. Get to know the faces behind our pioneering work and see why we are trusted partners in the journey from concept to cure.
Connect with us
BioEurope, Stockholm, November 2024
Once again we're off to BioEurope to talk everything VHH and learn from the experts in the field of antibody therapies.
World ADC, San Diego, November 2024
It's time for World ADC again, this year hosted in San Diego. Be sure to meet with our Business Development and R&D teams to discuss your VHH...
Stay up to date
Isogenica Ltd. and Axxam S.p.A. Announce Collaboration to Provide Unique VHH Antibody Discovery Solutions
Isogenica is pleased to welcome both Paul Clewlow and Trevor Phillips as our new Non-Executive Directors to the team.
Isogenica is proud to announce two new Non-Executive Directors
Isogenica is pleased to welcome both Paul Clewlow and Trevor Phillips as our new Non-Executive Directors to the team.
Isogenica announces two Pioneering Collaborations with an Antibody Research and License Agreement, and an Asset Evaluation Deal
Isogenica, a leading innovator in VHH antibodies, is proud to unveil two significant collaborations, demonstrating the company’s commitment to advancing healthcare through cutting-edge research and development.